Inhibikase Therapeutics, Inc. — Q2 2021 Form 10-Q Summary
Business Context and Reporting Period
Inhibikase Therapeutics is a clinical-stage pharmaceutical company developing therapeutics for Parkinson’s disease and related disorders, including gastrointestinal complications. Its lead program, IkT-148009, is a small-molecule Abelson tyrosine kinase inhibitor. The company is also developing IkT-001Pro, a prodrug candidate for stable-phase chronic myelogenous leukemia.
This unaudited Form 10-Q covers the three and six months ended June 30, 2021. The company had 25,133,345 common shares outstanding as of July 31, 2021 and reported no commercial product revenue.
Financial Results and Key Metrics
| Metric | Three Months Ended June 30, 2021 | Three Months Ended June 30, 2020 | Six Months Ended June 30, 2021 | Six Months Ended June 30, 2020 |
|---|---|---|---|---|
| Grant revenue | $1.36 million | $0.22 million | $2.77 million | $0.49 million |
| Research and development expense | $2.38 million | $0.26 million | $4.81 million | $0.55 million |
| Selling, general and administrative expense | $1.61 million | $0.37 million | $3.21 million | $0.90 million |
| Loss from operations | $(2.63) million | $(0.41) million | $(5.25) million | $(0.95) million |
| Net loss | $(2.64) million | $(0.42) million | $(5.27) million | $(0.97) million |
| Net loss per share | $(0.22) | $(0.05) | $(0.47) | $(0.12) |
- Q2 operating and net margins were approximately negative 193%; six-month operating and net margins were approximately negative 190%, reflecting the company’s pre-commercial development stage.
- Net cash used in operating activities was $8.18 million for the six months ended June 30, 2021, compared with $0.26 million in the prior-year period.
- Net cash provided by financing activities was $41.06 million, primarily from the June 2021 public offering.
- Cash increased to $46.84 million at June 30, 2021, from $13.95 million at December 31, 2020.
- Working capital was $47.30 million, and the accumulated deficit was $20.30 million.
- Total liabilities were $2.16 million, including $248,911 of notes payable due in 2022. The PPP loan was forgiven during the period.
- The June 2021 offering issued 15 million shares at $3.00 per share and generated approximately $41.1 million of net proceeds after offering costs, underwriting discounts and commissions.
Material Changes Versus the Prior Comparable Period
- Q2 grant revenue increased 521% to $1.36 million; six-month grant revenue increased 465% to $2.77 million. More than 90% of quarterly revenue came from the U.S. government through federal research grants.
- Q2 research and development expense increased 805% to $2.38 million, primarily due to higher grant-related research spending and expenditures associated with the Phase 1 Parkinson’s disease trial.
- Q2 selling, general and administrative expense increased 335% to $1.61 million, driven by public-company costs, director and officer insurance, legal and professional fees, investor relations, consulting, and stock-based compensation.
- The six-month net loss increased to $5.27 million from $0.97 million as development and public-company operating costs expanded.
- Shares outstanding increased substantially because of the June 2021 offering, from 10,050,849 at December 31, 2020 to 25,133,345 at June 30, 2021, creating significant dilution for existing holders.
Guidance, Outlook, Risks, and Unusual Items
- Management estimated that cash and working capital at June 30, 2021 would fund normal operations into the first half of fiscal 2023, while also stating that substantial additional funding would be needed for operations beyond 2022.
- Following FDA agreement in July 2021, the company planned to begin dosing Parkinson’s disease patients in a Phase 1b study during the third quarter of 2021. Management also expected to report full Phase 1 results, complete chronic toxicology studies, and initiate a Phase 2 efficacy study, subject to FDA agreement on protocol design.
- The company remained on track to submit an Investigational New Drug application for IkT-001Pro in the third quarter of 2021 and indicated that clinical development could potentially be completed in 2022, subject to FDA discussions and additional funding.
- Management expects research and development expenses and losses to increase as clinical development advances. No material product-sales revenue is expected unless and until a product receives regulatory approval and is commercialized.
- Key risks include clinical-trial failure or delay, regulatory uncertainty, inability to obtain additional financing, dilution from future equity offerings, manufacturing and supply-chain constraints, intellectual-property risks, competition, and dependence on grant funding.
- COVID-19 could delay enrollment, patient visits, trial execution, manufacturing, distribution, and regulatory timelines, although the company reported no material operational impact during the six months ended June 30, 2021.
- The company reported recurring losses and prepared its financial statements on a going-concern basis. It stated that it may need additional equity, debt, grant, licensing, or collaboration financing.
- Non-cash expenses included $913,607 of stock-based compensation and $477,183 of warrant expense during the first six months of 2021. The company also issued a warrant for 750,000 shares to the underwriters of the June offering, exercisable beginning June 15, 2022 at $3.75 per share.
Important Facts for Investors to Verify
- Verify the actual enrollment, safety, pharmacokinetic, and efficacy outcomes of the IkT-148009 Phase 1 and planned Phase 1b studies.
- Confirm whether the planned third-quarter 2021 IND submission for IkT-001Pro occurred and whether the FDA accepted or cleared the proposed development path.
- Assess the company’s cash runway against its stated plan, monthly operating cash burn, expected clinical-trial costs, and anticipated need for financing beyond 2022.
- Review dilution exposure from outstanding options and warrants; 5,186,570 shares were reserved for exercise at June 30, 2021.
- Evaluate the sustainability and timing of federal grant revenue, including the reported $1.55 million of active grants and $772,420 reportedly remaining available in U.S. Treasury-held accounts as of April 30, 2021.
- Track whether clinical, toxicology, manufacturing, regulatory, or COVID-19-related delays alter the company’s development timelines or cash requirements.